2019
Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014
Tabakin AL, Shinder BM, Kim S, Rivera-Nunez Z, Polotti CF, Modi PK, Sterling JA, Farber NJ, Radadia KD, Parikh RR, Kim IY, Saraiya B, Mayer TM, Singer EA, Jang TL. Retroperitoneal Lymph Node Dissection as Primary Treatment for Men With Testicular Seminoma: Utilization and Survival Analysis Using the National Cancer Data Base, 2004-2014. Clinical Genitourinary Cancer 2019, 18: e194-e201. PMID: 31818649, DOI: 10.1016/j.clgc.2019.10.018.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultFollow-Up StudiesHumansKaplan-Meier EstimateLymph Node ExcisionLymph NodesLymphatic MetastasisMaleMiddle AgedNeoplasm StagingOrchiectomyRegistriesRetroperitoneal SpaceRetrospective StudiesSeminomaSurvival RateTesticular NeoplasmsTestisTreatment OutcomeUnited StatesYoung AdultConceptsRetroperitoneal lymph node dissectionPrimary retroperitoneal lymph node dissectionLymph node dissectionOverall survivalTesticular seminomaNode dissectionRole of RPLNDTesticular nonseminomatous germ cell tumorsNational Cancer Data BaseNonseminomatous germ cell tumorsPrimary testicular cancerFive-year OSFirst-line treatmentKaplan-Meier methodOngoing prospective trialsGerm cell tumorsIIB diseaseOS ratesPrimary chemotherapyPrimary therapyProspective trialFinal cohortStage IIATumor histologyClinical stageA Case Study Evaluating the Diagnosis and Treatment of a Rare Mesenchymal Tumor
Shinder B, Sack J, Sadimin E, Tunuguntla H. A Case Study Evaluating the Diagnosis and Treatment of a Rare Mesenchymal Tumor. Urology 2019, 131: e1-e2. PMID: 31247212, DOI: 10.1016/j.urology.2019.06.019.Peer-Reviewed Case Reports and Technical NotesConceptsCellular angiofibromaPainless right inguinal massRare mesenchymal tumorRight inguinal massBenign mesenchymal neoplasmLimited treatment optionsOval-shaped massSurgical excisionInguinal massMesenchymal tumorsMesenchymal neoplasmsCT scanTreatment optionsSpermatic cordImmunohistochemical analysisRadiographic featuresImaging modalitiesAngiofibromaDiagnostic casesCD34NeoplasmsTumorExcisionDesminCord
2017
Risk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study
Kim DK, Parihar JS, Kwon YS, Kim S, Shinder B, Lee N, Farber N, Ahlering T, Skarecky D, Yuh B, Ruel N, Kim WJ, Rha KH, Kim IY. Risk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study. Asian Journal Of Andrology 2017, 20: 9-14. PMID: 28440262, PMCID: PMC5753561, DOI: 10.4103/1008-682x.196852.Peer-Reviewed Original ResearchConceptsMetastatic prostate cancerCytoreductive prostatectomyUrinary incontinenceProstate cancerBlood lossRadical prostatectomyCare androgen-deprivation therapyBenefit of cytoreductionUrinary incontinence rateAndrogen deprivation therapyMulti-institutional clinical trialsIncidence of complicationsMajor complication rateOnly independent predictorLonger operative timeRisk of complicationsTertiary surgical centerMulti-institutional studyDeprivation therapyBony metastasesIncontinence ratesPerioperative complicationsComplication rateCRP groupIndependent predictors